Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …

Background Cardiac arrhythmias are associated with poorer outcomes in patients with heart
failure (HF), diabetes mellitus (DM), and chronic kidney disease (CKD). Previous studies …

Aim The use of sodium glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2
diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily …

Over the past two years, our understanding of anti-hyperglycemic medications used to treat
patients with type 2 diabetes (T2D) has fundamentally changed. Before the EMPA-REG …

Background In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2)
inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to …

Context: Canagliflozin is a sodium glucose cotransporter 2 inhibitor developed to treat type 2
diabetes mellitus (T2DM). Objective: The purpose of this study was to describe the effects of …

Inhibitors of sodium–glucose co-transporter type 2 (SGLT2) are proposed as a novel
approach for the management of type 2 diabetes mellitus (T2DM). Several compounds are …

Diabetic nephropathy (DN) is the most common cause of end-stage renal disease
worldwide. Blood glucose and blood pressure control reduce the risk of developing this …

Background Type 2 diabetes is closely related to an increased risk of atrial fibrillation (AF)
and atrial flutter (AFL). Whether sodium-glucose cotransporter 2 (SGLT2) inhibitors can …

Objective To estimate the association between the use of sodium glucose co-transporter-2
(SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies. Design …